J3285 HCPCS code: Injection, treprostinil, 1 mg
J3285 is the HCPCS Level II code for injection, treprostinil, 1 mg. In 2024 Medicare paid an average of $43.49 per service for J3285 across 2,228,070 services. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. The NCCI unit limit is 9 per day on outpatient hospital claims. Medicare volume fell 5% from 2022 to 2024 (2,333,115 to 2,228,070 services). In 2024, 32 suppliers billed Medicare for J3285 (purchases), serving 916 beneficiaries; California, Florida, Ohio accounted for 22% of services.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1E — Other drugs |
| Added | 2006-01-01 |
| Last action effective | 2006-01-01 |
Who bills J3285 (2024)
| Measure | Value |
|---|---|
| Suppliers billing rentals | — |
| Suppliers billing purchases | 32 |
| Referring clinicians | 419 |
| Medicare beneficiaries | 916 |
| States with claims | 43 |
| Share of services in top 3 states (California, Florida, Ohio) | 22% |
| Year | Suppliers | Beneficiaries |
|---|---|---|
| 2022 | 34 | 1,007 |
| 2023 | 36 | 937 |
| 2024 | 32 | 916 |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for J3285, 2022–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2022 | 2,333,115 | 1,007 | $56.56 | $44.65 |
| 2023 | 2,323,557 | 937 | $55.45 | $43.39 |
| 2024 | 2,228,070 | 916 | $55.58 | $43.49 |
States with the most J3285 services (2024)
| State | Services | Avg. paid |
|---|---|---|
| California | 242,300 | $43.52 |
| Florida | 131,538 | $43.55 |
| Ohio | 125,787 | $43.25 |
| New York | 111,509 | $43.59 |
| Illinois | 103,222 | $43.55 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| outpatient hospital claims | 9 | Prescribing Information |
| practitioner claims | 1 | Clinical: CMS Workgroup |
Medicare policy articles for this code
- A52507: External Infusion Pumps - Policy Article (CGS Administrators, LLC (DME MAC) Noridian Healthcare Solutions, LLC (DME MAC)) — mentions this code in its coding guidance
Covered diagnoses (460 ICD-10-CM codes)
The diagnoses most often listed as covered in the policy articles above:
| ICD-10-CM | Diagnosis | Articles listing it |
|---|---|---|
| C91.00 | Acute lymphoblastic leukemia not having achieved remission | 1 |
| C91.01 | Acute lymphoblastic leukemia, in remission | 1 |
| C91.02 | Acute lymphoblastic leukemia, in relapse | 1 |
| D80.0 | Hereditary hypogammaglobulinemia | 1 |
| D80.2 | Selective deficiency of immunoglobulin A [IgA] | 1 |
| D80.3 | Selective deficiency of immunoglobulin G [IgG] subclasses | 1 |
| D80.4 | Selective deficiency of immunoglobulin M [IgM] | 1 |
| D80.5 | Immunodeficiency with increased immunoglobulin M [IgM] | 1 |
| D80.6 | Antibody deficiency with near-normal immunoglobulins or with hyperimmunoglobulinemia | 1 |
| D80.7 | Transient hypogammaglobulinemia of infancy | 1 |
Showing 10 of 460. The full list, non-covered diagnoses and CSV export are in Caduvo.
What changed for J3285
- 2006-01-01: J3285 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J3285?
J3285 is the HCPCS Level II code for injection, treprostinil, 1 mg. Short descriptor: "Treprostinil injection".
How much does Medicare pay for J3285?
In 2024, the average Medicare payment was $43.49 per service (average allowed $55.58).
Does Medicare cover J3285?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
Which diagnoses support coverage for J3285?
Medicare policy articles that cite J3285 list 460 covered ICD-10-CM diagnosis codes across 1 article. The most cited include C91.00 (Acute lymphoblastic leukemia not having achieved remission), C91.01 (Acute lymphoblastic leukemia, in remission), C91.02 (Acute lymphoblastic leukemia, in relapse). A listed diagnosis is necessary but not sufficient; the policy's other criteria still apply.
How many units of J3285 can be billed per day?
9 on outpatient hospital claims; 1 on practitioner claims (NCCI medically unlikely edits).
Related J32 codes
- J3230 — Injection, chlorpromazine hcl, up to 50 mg
- J3240 — Injection, thyrotropin alpha, 0.9 mg, provided in 1.1 mg vial
- J3241 — Injection, teprotumumab-trbw, 10 mg
- J3243 — Injection, tigecycline, 1 mg
- J3244 — Injection, tigecycline (accord), not therapeutically equivalent to j3243, 1 mg
- J3245 — Injection, tildrakizumab, 1 mg
- J3246 — Injection, tirofiban hcl, 0.25 mg
- J3247 — Injection, secukinumab, intravenous, 1 mg
- J3250 — Injection, trimethobenzamide hcl, up to 200 mg
- J3260 — Injection, tobramycin sulfate, up to 80 mg
- J3262 — Injection, tocilizumab, 1 mg
- J3263 — Injection, toripalimab-tpzi, 1 mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J3285
- Watch J3285 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J3285
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.